Uren A, Yu J C, Li W, Chung I Y, Mahadevan D, Pierce J H, Heidaran M A
Laboratory of Cellular and Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Biol Chem. 1996 May 10;271(19):11051-4. doi: 10.1074/jbc.271.19.11051.
We have reported previously that a chimeric platelet-derived growth factor receptor (PDGFR) possessing the ligand binding domain of the alpha PDGFR and the intracellular domain of the beta PDGFR (alpha 340 beta 342 R) was markedly more efficient than the wild type alpha PDGFR (alpha RWT) in its ability to enhance PDGF-A transforming activity in NIH/3T3 fibroblasts. To determine the region within the cytoplasmic domain of beta PDGFR that confers this higher transforming activity, we generated several additional alpha/beta PDGFR chimerae. When a chimeric PDGFR possessing the first 933 amino-terminal amino acids from the alpha PDGFR and the final 165 amino acids from the carboxyl-terminal of the beta PDGFR (alpha 933 beta 942 R) was cotransfected with the PDGF-A gene into NIH/3T3 cells, it showed a similar high efficiency to enhance PDGF-A chain transforming activity as alpha 340 beta 342 R. However, when chimeric PDGFRs in which either the kinase insert domain (alpha beta RKI) or the last 79 amino acids from the carboxyl-terminal end of the beta PDGFR (alpha 1024 beta 1028 R) were substituted into alpha PDGFR sequences were cotransfected with PDGF-A, they showed similar low efficiencies in enhancing transforming activity as the alpha RWT. These results predicted that the 86 amino acids following the tyrosine kinase 2 domain of beta PDGFR (amino acid residues 942-1027) were responsible for the higher transforming activity of beta PDGFR. To confirm this finding, we next constructed a chimera in which amino acid residues 942-1028 of the beta PDGFR (alpha beta 942-1028R) were substituted for those in the alpha PDGFR. Cotransfection experiments indicated that alpha beta 942-1028R increased transforming activity of PDGF-A to similar extent as the alpha 933 beta 942R, or alpha 340 beta 342R. Therefore, our findings define a critical domain within the noncatalytic region of beta PDGFR intracellular domain that confers the higher focus forming activity mediated by the beta PDGFR.
我们之前报道过,一种嵌合型血小板衍生生长因子受体(PDGFR),它具有α型PDGFR的配体结合结构域和β型PDGFR的细胞内结构域(α340β342R),在增强NIH/3T3成纤维细胞中PDGF - A转化活性的能力方面,明显比野生型α型PDGFR(αRWT)更有效。为了确定β型PDGFR胞质结构域中赋予这种更高转化活性的区域,我们构建了几种额外的α/β型PDGFR嵌合体。当一个具有来自α型PDGFR的前933个氨基末端氨基酸和来自β型PDGFR羧基末端的最后165个氨基酸的嵌合型PDGFR(α933β942R)与PDGF - A基因共转染到NIH/3T3细胞中时,它在增强PDGF - A链转化活性方面显示出与α340β342R相似的高效率。然而,当将激酶插入结构域(αβRKI)或来自β型PDGFR羧基末端的最后79个氨基酸(α1024β1028R)替代到α型PDGFR序列中的嵌合型PDGFR与PDGF - A共转染时,它们在增强转化活性方面显示出与αRWT相似的低效率。这些结果预测,β型PDGFR酪氨酸激酶2结构域之后的86个氨基酸(氨基酸残基942 - 1027)负责β型PDGFR的更高转化活性。为了证实这一发现,我们接下来构建了一个嵌合体,其中β型PDGFR的氨基酸残基942 - 1028(αβ942 - 1028R)替代了α型PDGFR中的相应残基。共转染实验表明,αβ942 - 1028R将PDGF - A转化活性提高到与α933β942R或α340β342R相似的程度。因此,我们的研究结果确定了β型PDGFR细胞内结构域非催化区域内的一个关键结构域,该结构域赋予了β型PDGFR介导的更高的集落形成活性。